Taiwan’s Trust Bio-sonics Joins 20+ Global Startups in Kendall Square for LabCentral’s First International Soft-Landing Program
Date: 2026/ 9/ 30 Wed., Media: Global Bio & Investment
News Link:
Trust Bio-sonics Selected for LabCentral's Inaugural International Soft-Landing Program, Expanding into Boston's Kendall Square to Connect with the Global Biotech Ecosystem
Trust Bio-sonics has been selected to join "The Loop," the inaugural international biotech soft-landing program launched by LabCentral, a premier U.S.-based non-profit biotech incubator. Representing Taiwan among more than 20 selected startups from 10 countries and regions worldwide, Trust Bio-sonics is expanding its footprint into Kendall Square in Boston—the epicenter of global biotech innovation.
Participating through a joint initiative between LabCentral and Japan's Shonan Health Innovation Park (Shonan iPark), the Trust Bio-sonics team traveled to the U.S. in September for the Loop Week Summit and in-person mentoring sessions. Throughout the program, the team engaged in in-depth discussions with seasoned U.S. biotech mentors, global pharmaceutical executives, and fellow startup founders, gaining strategic insights on technology positioning, clinical development pathways, business models, and U.S. market entry.
Trust Bio-sonics specializes in the development of proprietary ultrasound microbubble technology. Its core pipeline includes TBS-002, a next-generation ultrasound enhancing agent, and TBS-602 R.E.A.C.H., a targeted ultrasound drug delivery platform. By harnessing precision ultrasound energy, this platform is designed to overcome biological delivery barriers for small molecules, biologics, and gene therapies, enabling more efficient drug penetration into target tissues to enhance therapeutic efficacy.
Through this immersive experience in Boston, Trust Bio-sonics has not only established vital international industry connections but also recognized tremendous potential for deeper collaboration between the Taiwan and U.S. biotech ecosystems. Moving forward, the company will continue to leverage global partnerships and local resources to accelerate the international expansion and clinical development of its ultrasound drug delivery technology across immuno-oncology and gene therapy.
Note: In clinical trial protocols, the ultrasound contrast agent TBS-002 is officially designated as NH002 Injectable Suspension (Perflutren Lipid Microspheres).

